I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Vertex Pharmaceuticals (VRTX) recently announced strong financial results with Q2 2025 revenue increasing to $2,965 million from $2,646 million in Q2 2024, and net income turning positive. Despite ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock reached a 52-week low, closing at $377.78. The biotech giant, with a market capitalization of $97.2 billion, has maintained relatively low price ...

Vertex Pharmaceuticals reported a robust 12% increase in total revenue for the second quarter of 2025, achieving a monumental ...

Investing.com -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock fell 7% after the company announced that its investigational pain medication failed to meet the primary endpoint in a Phase 2 ...